[Thrombolytic treatment with urokinase (author's transl)].
Compared with streptokinase, thrombolytic treatment with urokinase has the advantages of being better tolerated and of practically unlimited applicability. Its disadvantage is the high cost. A good lytic action can be obtained with a dosage of 150,000 Ploug Units/12 hours for a duration of lysis of 8-14 days combined with heparin, the therapy being monitored by determination of the products of fibrinolysis. This dosage is not possible if the time factor plays a decisive role in the success of the treatment, e.g. in myocardial infarction. Urokinase is indicated when streptokinase cannot be used, or if continuation of the streptokinase therapy is necessary because of extensive thromboses.
D000328:Adult; D003365:Costs and Cost Analysis; D004359:Drug Therapy, Combination; D010450:Endopeptidases / Q000627:therapeutic use*; D005260:Female; D005268:Femoral Vein; D005337:Fibrin / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D010388:Pelvis; D013290:Streptococcal Infections / Q000150:complications; D013300:Streptokinase / Q000627:therapeutic use; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy*; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014684:Venae Cavae
D005337:Fibrin; D006493:Heparin; D010450:Endopeptidases; D013300:Streptokinase; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator
Thrombolytische Therapie mit Urokinase